Format

Send to

Choose Destination
See comment in PubMed Commons below
BMJ. 2002 Aug 3;325(7358):243.

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study.

Author information

1
Pharmaceutical Health Services Research Department, School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA.

Abstract

OBJECTIVE:

To quantify the association between olanzapine and diabetes.

DESIGN:

Population based nested case-control study.

SETTING:

United Kingdom based General Practice Research Database comprising 3.5 million patients followed between 1987 and 2000.

PARTICIPANTS:

19 637 patients who had been diagnosed as having and treated for schizophrenia. 451 incident cases of diabetes were matched with 2696 controls.

MAIN OUTCOME MEASURES:

Diagnosis and treatment of diabetes.

RESULTS:

Patients taking olanzapine had a significantly increased risk of developing diabetes than non-users of antipsychotics (odds ratio 5.8, 95% confidence interval 2.0 to 16.7) and those taking conventional antipsychotics (4.2, 1.5 to 12.2). Patients taking risperidone had a non-significant increased risk of developing diabetes than non-users of antipsychotics (2.2, 0.9 to 5.2) and those taking conventional antipsychotics (1.6, 0.7 to 3.8).

CONCLUSION:

Olanzapine is associated with a clinically important and significant increased risk of diabetes.

PMID:
12153919
PMCID:
PMC117636
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center